SAFETY OF THE BLOOD-SUPPLY - SURROGATE TESTING AND TRANSMISSION OF HEPATITIS-C IN PATIENTS AFTER MASSIVE TRANSFUSION

被引:27
作者
MORRIS, JA
WILCOX, TR
REED, GW
HUNTER, EB
WALLAS, CH
STEANE, EA
SHOTTS, SD
VITSKY, JL
机构
[1] VANDERBILT UNIV,SCH MED,DEPT SURG,NASHVILLE,TN 37212
[2] VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37212
[3] VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37212
[4] VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37212
[5] AMER RED CROSS,NASHVILLE,TN
关键词
D O I
10.1097/00000658-199405000-00010
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To define a risk profile for post-transfusion hepatitis C in patients receiving massive transfusion. Summary Background Data Hepatitis C accounts for more than 90% of post-transfusion hepatitis. Methods Two-hundred twenty-one of 8,765 consecutive trauma admissions to a Level I trauma center received more than 20 units of erythrocytes. Sixty-nine survivors had positive viral serologic tests at least 1 year after transfusion. Surrogate testing for hepatitis C using alanine aminotransferase (ALT) levels and antibodies to hepatitis B core antigen (Core) began in October 1986 and January 1987, respectively. Donor blood for group 1 (pre-ALT/Core) was transfused before surrogate screening was introduced. Donor blood for group 2 (post-ALT/Core) was transfused after surrogate screening. Results Sixty-nine patients received blood products from 4,987 donors (mean, 72.3 units of exposure). No patient tested positive for antibodies to hepatitis B surface antigen, human immunodeficiency virus, or human T-lymphotrophic virus type 1. However 23.2% tested positive for hepatitis C virus (HCV) as measured by a second-generation enzyme immunoassay (HCV 2.0) and a recombinant immunoblot assay (RIBA), and 21.7% tested positive by HCV 1.0. Antibodies to Core were found in 8.7% of patients. The risk for post-transfusion hepatitis C per unit of exposure is estimated to be 1.52% group 1 (pre-ALT/Core) and 0.239% for group 2 (post-ALT/Core). Conclusions The introduction of ALT/Core donor screening by a blood bank reduced the incidence of post-transfusion hepatitis C by 84%. The risk for post-transfusion hepatitis C depends on units of exposure, screening techniques, and prevalence of hepatitis C in the donor population. In our community, the risk for post-transfusion hepatitis C is less than 0.2% per unit of exposure. The population of massively transfused patients may serve as our effective resource for monitoring the safety of the blood supply.
引用
收藏
页码:517 / 526
页数:10
相关论文
共 21 条
[1]   HEPATITIS-C VIRUS-INFECTION IN POSTTRANSFUSION HEPATITIS - AN ANALYSIS WITH 1ST-GENERATION AND 2ND-GENERATION ASSAYS [J].
AACH, RD ;
STEVENS, CE ;
HOLLINGER, FB ;
MOSLEY, JW ;
PETERSON, DA ;
TAYLOR, PE ;
JOHNSON, RG ;
BARBOSA, LH ;
NEMO, GJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (19) :1325-1329
[2]   SERUM ALANINE AMINOTRANSFERASE OF DONORS IN RELATION TO THE RISK OF NON-A,NON-B HEPATITIS IN RECIPIENTS - THE TRANSFUSION-TRANSMITTED VIRUSES STUDY [J].
AACH, RD ;
SZMUNESS, W ;
MOSLEY, JW ;
HOLLINGER, FB ;
KAHN, RA ;
STEVENS, CE ;
EDWARDS, VM ;
WERCH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (17) :989-994
[3]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[4]   DONOR TRANSAMINASE AND RECIPIENT HEPATITIS - IMPACT ON BLOOD-TRANSFUSION SERVICES [J].
ALTER, HJ ;
PURCELL, RH ;
HOLLAND, PV ;
ALLING, DW ;
KOZIOL, DE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 246 (06) :630-634
[5]   CLINICAL AND SEROLOGICAL ANALYSIS OF TRANSFUSION-ASSOCIATED HEPATITIS [J].
ALTER, HJ ;
HOLLAND, PV ;
MORROW, AG ;
PURCELL, RH ;
FEINSTONE, SM ;
MORITSUGU, Y .
LANCET, 1975, 2 (7940) :838-841
[6]  
ALTER HJ, 1984, ANN INTERN MED, V101, P860
[7]  
CHOO QL, 1989, SCIENCE, V244, P362
[8]  
DAVIS GL, 1989, NEW ENGL J MED, V321, P1051
[9]  
DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439
[10]   HEPATITIS-C-ASSOCIATED HEPATOCELLULAR-CARCINOMA [J].
HASAN, F ;
JEFFERS, LJ ;
DEMEDINA, M ;
REDDY, KR ;
PARKER, T ;
SCHIFF, ER ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
HEPATOLOGY, 1990, 12 (03) :589-591